Research Plan

Research Programme 1: Protein-protein interactions (RP1)

• WP 1.1. Targeting enzymes involved in extracellular matrix degradation (M.Mareš)  
• WP 1.2. Targeting protein-protein interactions in leukemia (P.Řezáčová)  
• WP 1.3. Protein-protein interactions targeted by computational fragment-based design (P.Hobza)  
• WP 1.4. Targeting Ameloblastin, an intrinsically disordered protein from enamel matrix (J.Vondrášek, P.Bouř)  
• WP 1.5. Development of insulin mimetics (J.Jiráček, U.Jahn, J.Konvalinka)  
• WP 1.6. Targerting insulin storage forms in pancreatic secretory granules (J.Jiráček)  
• WP 1.7. Targeting interactions of membrane receptors with other proteins and peptidomimetics (J.Lazar)  
• WP 1.8. Controlling specific protein-protein interactions using nanoparticles (P.Cígler, P.Bouř)  
• WP 1.9. Targeting protein-protein interactions of host-virus interface (R.Nencka, E.Bouřa)  
• WP 1.10. Targeting interaction of HBV core, precore and X proteins with host cell machineries (I.Pichová, J.Weber, J.Cvačka)  
• WP 1.11. Development of compounds disrupting protein-protein interaction in influenza A polymerase (J.Konvalinka)  

Research Programme 2: Protein-membrane interactions (RP2)

• WP 2.1. Targeting and crossing complex cellular membranes (P.Jungwirth, U.Jahn, J.Lazar, P.Bouř)  
• WP 2.2. Inhibition of intramembrane catalysis and protein-protein interactions for novel targeting of inflammatory and cancer pathologies (K.Stříšovský)  
• WP 2.3. Targeting host-virus interactions on membranes (E.Bouřa, R.Nencka)  

Research Programme 3: Protein-nucleic acid interactions (RP3)

• WP 3.1. Development of aptamers against oncogenic factors (M.Hocek)  
• WP 3.2. Development of functional DNA motifs that target HBV (I.Pichová, E.Curtis, M.Hocek)  
• WP 3.3. Development of anti-HBV compounds targeting STING protein (G.Birkuš, R.Nencka)  
• WP 3.4. Development of Nanoparticles for targeted gene editing (J.Konvalinka)  
• WP 3.5. Engineering of peptide scaffolds disrupting protein-nucleic acid interactions – a case of EST and HIF-1 transcription factors involved in cancer (J.Vondrášek)